{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:30:36Z","timestamp":1790181036972,"version":"4.1.0"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Adverse Drug Reactions (ADRs) can occur with all medicines even after successful extensive clinical trials. ADRs result in more than 10% of hospital admissions worldwide. In Ghana, there has been an increase of 13 to 126 ADR reports per million population from 2012 to 2018. ADR Surveillance System (ADRSS) also known as pharmacovigilance has been put in place by the Ghana Food and Drugs Authority (FDA) to collect and manage suspected ADR reports and communicate safety issues to healthcare professionals and the general public. The ADRSS in Ho Municipality was evaluated to assess the extent of reporting of ADRs and the system\u2019s attributes; determine its usefulness, and assess if the ADRSS is achieving its objectives.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We evaluated the ADRSS of the Ho Municipality from January 2015 to December 2019. Quantitative data were collected through interviews and review of records. We adapted the updated CDC guidelines to develop interview guides and a checklist for data collection. Attributes reviewed included simplicity, data quality, acceptability, representativeness, timeliness, sensitivity, predictive value positive and stability.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>We found a total of 1,237 suspected ADR during the period, of which only 36 (3%) were reported by healthcare professionals in the Ho Municipality to the National Pharmacovigilance Centre (NPC). Only 43.9% of health staff interviewed were familiar with the ADRSS and its reporting channel. Staff who could mention at least one objective of the ADRSS were 34.2%, and 12.2% knew the timelines for reporting ADR. Reports took a median time of 41 (IQR = 25, 81) days from reporter to NPC. Reports sent on time constituted 37.5%. Fully completed case forms constituted 77.1% and the predictive value positive (PVP) was 20%. About 53% of ADRs were reported for female patients. Up to 88.9% of ADRs were classified as drug related. Anti-tuberculosis agents and other antibiotics constituted (40.6%) and (18.8%) of all reports. The ADRSS was not integrated into the disease surveillance and response system of Ghana\u2019s Health Service and so was not flexible to changes. A dedicated ADR surveillance officer in regions helped with the system\u2019s stability. Data from Ghana feeds into a WHO database for global decision making.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>There was under-reporting of ADRs in the Ho Municipality from January 2015 to December 2019. The ADR surveillance system was simple, stable, acceptable, representative, had a strong PVP but was not flexible or timely. The ADRSS was found useful and partially met its objectives.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0291482","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T17:22:57Z","timestamp":1694539377000},"page":"e0291482","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["Under-reporting of adverse drug reactions: Surveillance system evaluation in Ho Municipality of the Volta Region, Ghana"],"prefix":"10.1371","volume":"18","author":[{"given":"Richard Osei","family":"Buabeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0273-4337","authenticated-orcid":true,"given":"Paul","family":"Dsane-Aidoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaw K.","family":"Asamoah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0281-5321","authenticated-orcid":true,"given":"Delia Akosua","family":"Bandoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne Adu","family":"Boahen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1785-796X","authenticated-orcid":true,"given":"George Tsey","family":"Sabblah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delese Mimi","family":"Darko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles Noora","family":"Lwanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donne Kofi","family":"Ameme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Kenu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,9,12]]},"reference":[{"key":"pone.0291482.ref001","doi-asserted-by":"crossref","first-page":"e0186631","DOI":"10.1371\/journal.pone.0186631","article-title":"Predictors of adverse drug reaction-related hospitalisation in Southwest Ethiopia: A prospective cross-sectional study.","volume":"12","author":"MT Angamo","year":"2017","journal-title":"PLoS One"},{"key":"pone.0291482.ref002","first-page":"95","article-title":"Adverse Drug Reactions Causing Admission to Medical Wards: A Cross-Sectional Survey at 4 Hospitals in South Africa.","author":"JP Mouton","year":"2016","journal-title":"Medicine"},{"key":"pone.0291482.ref003","first-page":"1","author":"S Schatz","year":"2015","journal-title":"Adverse Drug Reactions. Pharm Pract (Granada)"},{"key":"pone.0291482.ref004","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.4103\/0976-500X.120957","article-title":"Clinical and economic burden of adverse drug reactions.","volume":"4","author":"J Sultana","year":"2013","journal-title":"J Pharmacol Pharmacother"},{"key":"pone.0291482.ref005","first-page":"153","article-title":"Incidence, Preventability, and Impact of Adverse Drug Events (ADEs) and Potential ADEs in Hospitalized Children in New Zealand.","volume":"11","author":"DL Kunac","year":"2012","journal-title":"Pediatric Drugs 2009 11:2"},{"key":"pone.0291482.ref006","first-page":"445","article-title":"Counting the Costs of Drug-Related Adverse Events.","volume":"15","author":"TJ White","year":"2012","journal-title":"PharmacoEconomics 1999 15:5"},{"key":"pone.0291482.ref007","first-page":"847","article-title":"Adverse-Drug-Reaction-Related Hospitalisations in Developed and Developing Countries: A Review of Prevalence and Contributing Factors.","volume":"39","author":"MT Angamo","year":"2016","journal-title":"Drug Safety 2016 39:9"},{"key":"pone.0291482.ref008","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1001\/jama.1997.03540280045032","article-title":"The Costs of Adverse Drug Events in Hospitalized Patients","volume":"277","author":"DW Bates","year":"1997","journal-title":"JAMA"},{"key":"pone.0291482.ref009","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4103\/0253-7613.150344","article-title":"Under-reporting of adverse drug reactions: A challenge for pharmacovigilance in India.","volume":"47","author":"VR Tandon","year":"2015","journal-title":"Indian J Pharmacol"},{"key":"pone.0291482.ref010","first-page":"19","article-title":"Determinants of Under-Reporting of Adverse Drug Reactions.","volume":"32","author":"E Lopez-Gonzalez","year":"2012","journal-title":"Drug Safety 2008 32:1"},{"key":"pone.0291482.ref011","first-page":"385","article-title":"Under-Reporting of Adverse Drug Reactions.","volume":"29","author":"L Hazell","year":"2012","journal-title":"Drug Safety 2006 29:5"},{"key":"pone.0291482.ref012","doi-asserted-by":"crossref","unstructured":"Olsson S, Pal SN, Dodoo A. Pharmacovigilance in resource-limited countries. Http:\/\/DxDoiOrg\/101586\/1751243320151053391 2015;8:449\u201360. https:\/\/doi.org\/10.1586\/17512433.2015.1053391.","DOI":"10.1586\/17512433.2015.1053391"},{"key":"pone.0291482.ref013","first-page":"911","article-title":"Patients\u2019 Perspectives on Adverse Drug Reaction Reporting in a Developing Country: A Case Study from Ghana.","volume":"40","author":"GT Sabblah","year":"2017","journal-title":"Drug Safety 2017 40:10"},{"key":"pone.0291482.ref014","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4314\/gmj.v55i1.3","article-title":"Adverse drug reaction reporting by community pharmacists in the Greater Accra Region of Ghana, 2016.","volume":"55","author":"JY Osei","year":"2021","journal-title":"Ghana Med J"},{"key":"pone.0291482.ref015","first-page":"4","article-title":"Spontaneous Reporting for 2018","volume":"2019","journal-title":"DrugLens"},{"key":"pone.0291482.ref016","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3325\/cmj.2018.59.124","article-title":"Adverse drug reaction reporting and development of pharmacovigilance systems in Bosnia and Herzegovina, Croatia, Serbia, and Montenegro: A retrospective pharmacoepidemiological study.","volume":"59","author":"U Glamo\u010dlija","year":"2018","journal-title":"Croat Med J"},{"key":"pone.0291482.ref017","author":"R Rosli","year":"2016","journal-title":"A Retrospective Analysis of Spontaneous Adverse Drug Reactions Reports Relating to Paediatric Patients"},{"key":"pone.0291482.ref018","first-page":"7","author":"DM Darko","year":"2013","journal-title":"Spontaneous Reporting for 2012. DrugLens"},{"key":"pone.0291482.ref019","author":"echnical Guidelines for Integrated Disease Surveillance and Response in Ghana","year":"2002","journal-title":"TAccra"},{"key":"pone.0291482.ref020","year":"2018","journal-title":"WHO Global Benchmarking Tool (Gbt) For Evaluation Of National Regulatory System Of Medical Products Vigilance (Vl): Indicators And Fact Sheets"},{"key":"pone.0291482.ref021","year":"2014","journal-title":"WHO Pharmacovigilance Indicators: A Practical Manual For The Assessment Of Pharmacovigilance Systems"},{"key":"pone.0291482.ref022","year":"2001","journal-title":"Updated Guidelines for Evaluating Public Health Surveillance Systems"},{"key":"pone.0291482.ref023","author":"2010 Population & Housing Census: District Analytical Report","year":"2014","journal-title":"Ho Municipality:"},{"key":"pone.0291482.ref024","year":"2020","journal-title":"Republic Of Ghana Composite Budget For 2021\u20132024 Programme Based Budget Estimates For 2021 Ho Municipal"},{"key":"pone.0291482.ref025","year":"2020","journal-title":"Technical Advisory Committees, Ghana Food And Drugs Authority | Home"},{"key":"pone.0291482.ref026","doi-asserted-by":"crossref","DOI":"10.1093\/heapol\/czz107","article-title":"Use of evidence and negotiation in the review of national standard treatment guidelines and essential medicines list: experience from Ghana Health Policy Plan.","author":"A Koduah","year":"2019"},{"key":"pone.0291482.ref027","first-page":"1","article-title":"Instruction for the Restriction of Importation, Manufacture and Registration of Codeine-containing Cough Syrups Instrument, 2018.","author":"K. Agyeman-Manu","year":"2018","journal-title":"Executive Instrument 167"},{"key":"pone.0291482.ref028","first-page":"26","author":"G. Nahler","year":"2009","journal-title":"CIOMS I form. Dictionary of Pharmaceutical Medicine"},{"key":"pone.0291482.ref029","author":"The use of the WHO-UMC system for standardised case causality assessment","year":"2013","journal-title":"WHO"},{"key":"pone.0291482.ref030","first-page":"386","article-title":"Review Article Causality Assessment in Pharmacovigilance: A Step Towards Quality Care.","volume":"1","author":"RC Hire","year":"2013","journal-title":"Scholars Journal of Applied Medical Sciences (SJAMS)"},{"key":"pone.0291482.ref031","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4103\/0976-9668.107289","article-title":"Knowledge, attitudes, and practice of doctors to adverse drug reaction reporting in a teaching hospital in India: An observational study.","volume":"4","author":"SA Khan","year":"2013","journal-title":"J Nat Sci Biol Med"},{"key":"pone.0291482.ref032","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.4103\/jfmpc.jfmpc_831_21","article-title":"Agreement between WHO-UMC causality scale and the Naranjo algorithm for causality assessment of adverse drug reactions.","volume":"10","author":"A Shukla","year":"2021","journal-title":"J Family Med Prim Care"},{"key":"pone.0291482.ref033","doi-asserted-by":"crossref","first-page":"100064","DOI":"10.1016\/j.rcsop.2021.100064","article-title":"Causality assessment of adverse drug reactions by applying a global introspection method in a high complexity hospital.","volume":"3","author":"R Rezende de Menezes","year":"2021","journal-title":"Exploratory Research in Clinical and Social Pharmacy"},{"key":"pone.0291482.ref034","first-page":"27","article-title":"Evaluation of the adverse drug reaction surveillance system Kadoma City, Zimbabwe 2015","author":"C Muringazuva","year":"2017","journal-title":"Pan African Medical Journal"},{"key":"pone.0291482.ref035","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40264-015-0387-4","article-title":"Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase \u00d2.","volume":"39","author":"HH Ampadu","year":"2016","journal-title":"Drug Saf"},{"issue":"6","key":"pone.0291482.ref036","first-page":"515","volume":"31","author":"J De Langen","year":"2008","journal-title":"Adverse Drug Reaction Reporting by Patients in the Netherlands Three Years of Experience. Drug Saf"},{"key":"pone.0291482.ref037","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00228-010-0865-7","article-title":"Motives for reporting adverse drug reactions by patient-reporters in the Netherlands","volume":"66","author":"F Van Hunsel","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"pone.0291482.ref038","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/jcph.1148","article-title":"Adverse Drug Reactions Reported by Healthcare Professionals: Reaction Characteristics and Time to Reporting.","volume":"58","author":"AK Aung","year":"2018","journal-title":"The Journal of Clinical Pharmacology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0291482","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T17:23:12Z","timestamp":1694539392000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0291482"}},"subtitle":[],"editor":[{"given":"Mergan","family":"Naidoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,9,12]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0291482","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,12]]}}}